Rebecca Joy Ulrich

Rebecca Joy Ulrich

Auto-generated profile, based on publicly available information

Rebecca Joy Ulrich

Infectious Disease and Microbiome Program

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SMStephen E. Motika
Stephen E. Motika
RURebecca J. Ulrich
Rebecca J. Ulrich
EGEmily J. Geddes
Emily J. Geddes
HLHyang Yeon Lee
Hyang Yeon Lee
GLGee W. Lau
Gee W. Lau
PHPaul J. Hergenrother
Paul J. Hergenrother

10 August 2022 in ACS Central Science
Verified
Journal Article
Open access
EPErica N. Parker
Erica N. Parker
BCBrett N. Cain
Brett N. Cain
BHBehnoush Hajian
Behnoush Hajian
RURebecca J. Ulrich
Rebecca J. Ulrich
EGEmily J. Geddes
Emily J. Geddes
PHPaul J. Hergenrother
Paul J. Hergenrother
Genomic studies and experiments with permeability-deficient strains have revealed a variety of biological targets that can be engaged to kill Gram-negative bacteria. However, the formidable outer membrane and promiscuous efflux pumps of these pathogens prevent many candidate antibiotics from reaching these targets. One such promising target is the enzyme FabI, which catalyzes the rate-determining step in bacterial fatty acid biosynthesis. Notably, FabI inhibitors have advanced to clinical trials for Staphylococcus aureus infections but not for infections caused by Gram-negative bacteria. Here, we synthesize a suite of FabI inhibitors whose structures fit permeation rules for Gram-negative bacteria and leverage activity against a challenging panel of Gram-negative clinical isolates as a filter for advancement. The compound to emerge, called fabimycin, has impressive activity against >200 clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, and does not kill commensal bacteria. X-ray structures of fabimycin in complex with FabI provide molecular insights into the inhibition. Fabimycin demonstrates activity in multiple mouse models of infection caused by Gram-negative bacteria, including a challenging urinary tract infection model. Fabimycin has translational promise, and its discovery provides additional evidence that antibiotics can be systematically modified to accumulate in Gram-negative bacteria and kill these problematic pathogens.

22 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AVArchit Kumar Vasan
Archit Kumar Vasan
NHNandan Haloi
Nandan Haloi
RURebecca Joy Ulrich
Rebecca Joy Ulrich
MMMary Elizabeth Metcalf
Mary Elizabeth Metcalf
PWPo-Chao Wen
Po-Chao Wen
Emad TajkhorshidEmad Tajkhorshid
Emad Tajkhorshid
Gram-negative bacteria pose a serious public health concern due to resistance to many antibiotics, caused by the low permeability of their outer membrane (OM). Effective antibiotics use porins in the OM to reach the interior of the cell; thus, understanding permeation properties of OM porins is instrumental to rationally develop broad-spectrum antibiotics. A functionally important feature of OM porins is undergoing open–closed transitions that modulate their transport properties. To characterize the molecular basis of these transitions, we performed an extensive set of molecular dynamics (MD) simulations of Escherichia coli OM porin OmpF. Markov-state analysis revealed that large-scale motion of an internal loop, L3, underlies the transition between energetically stable open and closed states. The conformation of L3 is controlled by H bonds between highly conserved acidic residues on the loop and basic residues on the OmpF β-barrel. Mutation of key residues important for the loop’s conformation shifts the equilibrium between open and closed states and regulates translocation of permeants (ions and antibiotics), as observed in the simulations and validated by our whole-cell accumulation assay. Notably, one mutant system G119D, which we find to favor the closed state, has been reported in clinically resistant bacterial strains. Overall, our accumulated ∼200 µs of simulation data (the wild type and mutants) along with experimental assays suggest the involvement of internal loop dynamics in permeability of OM porins and antibiotic resistance in Gram-negative bacteria. Significance Antibiotic resistance in Gram-negative pathogens has been identified as an urgent threat to human health by the World Health Organization. The major challenge with treating infections by these pathogens is developing antibiotics that can traverse the dense bacterial outer membrane (OM) formed by a mesh of lipopolysaccharides. Effective antibiotics permeate through OM porins, which have evolved for nutrient diffusion; however, the conformational states of these porins regulating permeation are still unclear. Here, we used molecular dynamics simulations, free energy calculations, Markov-state modeling, and whole-cell accumulation assays to provide mechanistic insight on how a porin shifts between open and closed states. We provide a mechanism of how Gram-negative bacteria confer resistance to antibiotics.

27 May 2019 in ACS Infectious Diseases
Verified
Journal Article
Closed access
NCNicholas Cutrona
Nicholas Cutrona
KGKyra Renee Gillard
Kyra Renee Gillard
RURebecca Joy Ulrich
Rebecca Joy Ulrich
MSMikaela Seemann
Mikaela Seemann
HMHeather Miller
Heather Miller
MBMeghan Blackledge
Meghan Blackledge

7 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJames E. Gomez
James E. Gomez
MSMatthew Y. Solomon
Matthew Y. Solomon
DHDiana K. Hunt
Diana K. Hunt
EGEmily J. Geddes
Emily J. Geddes
ABAustin N. Bond
Austin N. Bond
DHDeborah T. Hung
Deborah T. Hung
PROSPECT (PRimary screening Of Strains to Prioritize Expanded Chemistry and Targets) is an antimicrobial discovery platform based on chemical-genetic interaction (CGI) profiling of compounds against a pool of Mycobacterium tuberculosis ( Mtb) hypomorphs, each depleted of an essential gene. From prior screening data, we have now identified a novel N-oxolan-3-yl pyrazole carboxamide inhibitor (BRD1554) that had increased, selective activity against strains depleted of polyketide synthase 13 (Pks13), an essential enzyme in mycolic acid synthesis, and Rv2581c, an uncharacterized protein similar to glyoxylase II enzymes. Perturbagen CLass (PCL) analysis, a reference-based approach to mechanism of action (MOA) assignment from PROSPECT, predicted Pks13, a polyketide synthase with five catalytic domains responsible for the terminal condensation step in mycolic acid biosynthesis, was the likely target, potentially implicating the thioesterase domain. We synthesized a more active analogue while assigning the absolute stereochemistry of the active diastereomer, resulting in 1554-06-3R,4S with an MIC 90 of 3.0 µM against Mtb H37Rv. Exposure to 1554-06 led to the upregulation of the pks13 operon along with the iniBAC operon and other genes linked to mycolic acid synthesis. Isolation of mutants resistant to 1554-06 revealed single nucleotide polymorphisms in the thioesterase domain of Pks13. Finally, we biochemically confirmed that 1554-06 inhibits the activity of recombinant Pks13 thioesterase domain, with computational docking of 1554-06 steroisomers consistent with the stereospecific activity seen in whole cell assays. We found unique chemical genetic interactions between inhibitors of the different Pks13 domains and different detoxifying enzymes of Mtb , thus revealing novel gene-gene interactions. These results highlight how PROSPECT can not only immediately reveal, with domain-level resolution, the MOA of new whole-cell active chemical inhibitors of Mtb , allowing the integration of biological insight into compound triage and accelerated early development, but can also illuminate genetic interactions linked to those mechanisms that could inform predictions of synergy for antitubercular drug development.

13 May 2026 in ACS Infectious Diseases
Verified
Journal Article
Closed access
JGJames E. Gomez
James E. Gomez
MSMatthew Y. Solomon
Matthew Y. Solomon
DHDiana K. Hunt
Diana K. Hunt
EGEmily J. Geddes
Emily J. Geddes
ABAustin N. Bond
Austin N. Bond
DHDeborah T. Hung
Deborah T. Hung